Is Clovis's rociletinib better than other lung cancer treatments, FDA committee to be asked

11 April 2016

An advisory committee of the US Food and Drug Administration will question on Tuesday whether rociletinib, the lung cancer drug of USA-based Clovis Oncology (Nasdaq: CLVS), is any more effective than drugs which are already available.

However, ahead of the meeting, negative briefing papers from FDA staffers saw Clovis shares plunge as much as19% on Monday.

Rociletinib is indicated for the treatment of patients with epidermal growth factor receptor (EGFR) mutation positive metastatic non-small cell lung cancer, who have been previously treated with EGFR-targeted therapy and who have the EGFR T790M mutation, as detected by an FDA-approved test.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK